In a pooled analysis of two heart failure studies in those with and without T2D, semaglutide 2.4 mg produced an 18% reduction in NT-pro-BNP, with similar magnitude of reduction across differing baseline weights [39]. This evidence concerns the gene NPPB and type 2 diabetes mellitus.